A Diagnostics & Imaging Week

Mark Faupel, PhD, has been named CEO of SpectRx (Norcross, Georgia). Faupel previously served as president/COO and chief technical officer of the company.

Faupel succeeds Mark Samuels, who retired, effective May 11. Samuels will remain as a consultant to the company and maintain an office.

“Now that the SimpleChoice sale is completed and other transactions are nearing a close, I am stepping down as chairman and CEO,” Samuels said. “By focusing on bringing its non-invasive cervical cancer detection technology to market, I believe that the company is on the right path. I fully support the board of directors, management team and employees of the company, and I look forward to seeing SpectRx succeed.”

Faupel has more than 20 years of experience as a senior executive developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Prior to coming to SpectRx in 1998 as VP of Business Development and then co-founding Guided Therapeutics, Faupel was a senior executive and co-founder of Biofield.

“On behalf of the board, management and employees, I want to thank Mark for his service to the company over the years,” said John Imhoff, MD, SpectRx board member.

SpectRx is developing a rapid test for the early detection of disease that leads to cervical cancer using light to scan the cervix for disease. Designed to be painless and to provide results immediately, the test consists of a base unit and a single-patient-use disposable calibration and patient interface.